초록 ▼

This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or ma

This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.

대표청구항 ▼

1. A method of correlating cellular morphology with the presence of a cellular target nucleic acid sequence in a section of a tissue sample comprising the following steps: (a) staining the section of tissue sample with a morphological stain; (b) determining cellular morphology in the section of

1. A method of correlating cellular morphology with the presence of a cellular target nucleic acid sequence in a section of a tissue sample comprising the following steps: (a) staining the section of tissue sample with a morphological stain; (b) determining cellular morphology in the section of tissue sample; (c) hybridizing a first fluorescently labeled nucleic acid probe to the target nucleic acid sequence in the same section of tissue sample; (d) detecting the presence of the first nucleic acid probe in the section of tissue sample; and (e) correlating step (b) with step (d). 2. The method of claim 1, wherein the first nucleic acid probe is constructed to hybridize to the target nucleic acid sequence indicating a genetic abnormality selected from the group consisting of amplification, addition, substitution, translocation and deletion. 3. The method of claim 1, wherein amplification of the target nucleic acid sequence is determined in step (d). 4. The method of claim 3, wherein the target nucleic acid sequence is HER2/neu gene. 5. The method of claim 1, wherein the morphological stain used in step (a) does not significantly autofluoresce at the same wavelength as a fluorescent label of the first nucleic acid probe. 6. The method of claim 1, further comprising hybridizing a second fluorescently labeled nucleic acid probe to a nucleic acid sequence in the section of tissue sample, wherein the second nucleic acid probe comprises a fluorescent label distinguishable from a fluorescent label of the first nucleic acid probe. 7. The method of claim 6, wherein the second nucleic acid probe determines chromosome copy number. 8. The method of claim 1, wherein the morphological stain used in step (a) comprises xanthine dye and thiazine dye. 9. The method of claim 8, wherein the morphological stain is HEMA 3.RTM.. 10. The method of claim 1, wherein the tissue sample is selected from the group consisting of breast, prostate, ovary, colon, lung, endometrium, stomach, salivary gland and pancreas tissue sample. 11. The method of claim 1, wherein the target nucleic acid sequence is selected from the group consisting of HER2/neu gene and the centromere of chromosome 17. 12. The method of claim 1, wherein the first nucleic acid probe is labeled with a fluorescent label selected from the group consisting of Texas Red, fluorescein, phycocrytherin, rhodamine, phycocyanin, dansyl, umbelliferone, SPECTRUM GREEN.RTM., and SPECTRUM ORANGE.RTM.. 13. The method of claim 1, wherein the section of tissue sample is not destained prior to step (c). 14. The method of claim 1, wherein the section of tissue sample is obtained from fixed, paraffin-embedded tissue sample. 15. A method of correlating cellular morphology and the presence of a cellular target protein with the presence of a cellular target nucleic acid sequence in a section of a tissue sample, comprising the following steps: (a) staining the section of tissue sample with a morphological stain; (b) determining cellular morphology in the section of tissue sample; (c) contacting the section of tissue sample with an antibody which specifically binds to the target protein; (d) determining binding of the antibody to the section of tissue sample; (e) hybridizing a fluorescently labeled nucleic acid probe to the target nucleic acid sequence in the same section of tissue sample; (f) detecting the presence of the labeled nucleic acid probe in the section of tissue sample; and (g) correlating steps (b) and (d) with step (f).